Posts

Posted on

FranklinCovey and Simon & Schuster Launch New Book, The Leader’s Guide to Unconscious Bias: How to Reframe Bias, Cultivate Connection, and Create High-Performing Teams

FranklinCovey and Simon & Schuster Launch New Book, The Leader’s Guide to Unconscious Bias: How to Reframe Bias, Cultivate Connection, and Create High-Performing Teams

A Timely, Must-Have Guide for Leaders, Teams and Organizations to Reframe and Overcome Bias in the Workplace to Build High-Performing Cultures of Diversity, Inclusion and Equity

SALT LAKE CITY–(BUSINESS WIRE)–Franklin Covey Co. (NYSE: FC), a global firm specializing in organizational performance improvement, and Simon & Schuster, today announced the release of the new book, The Leader’s Guide to Unconscious Bias: How to Reframe Bias, Cultivate Connection, and Create High-Performing Teams.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201120005265/en/

FranklinCovey and Simon & Schuster Launch New Book, The Leader's Guide to Unconscious Bias: How to Reframe Bias, Cultivate Connection, and Create High-Performing Teams (Photo: Business Wire)

FranklinCovey and Simon & Schuster Launch New Book, The Leader’s Guide to Unconscious Bias: How to Reframe Bias, Cultivate Connection, and Create High-Performing Teams (Photo: Business Wire)

Co-authored by Pamela Fuller, FranklinCovey Thought Leader, Inclusion and Bias; Mark Murphy, FranklinCovey Senior Consultant; and Anne Chow, CEO of AT&T Business and FranklinCovey board member, the book is a timely, must-have guide for leaders, teams and organizations seeking to understand and overcome bias in their workplace to build cultures of diversity, inclusion, and equity.

“The need for this book has long been present,” said Anne Chow, co-author, CEO of AT&T Business. “But it’s never been more timely, as organizations around the world are now confronting their own biases. Addressing bias is one of the most important topics for individuals, organizations and communities to confront — meaningfully, purposefully, and with a desire to listen, learn, engage, and do better. Our book’s focus on unconscious bias and its impact on workplace performance addresses these very issues and serves as an invitation for leaders and organizations to develop and participate in constructive dialogues about inclusion, while implementing actions that drive both progress and performance.”

The Leader’s Guide to Unconscious Biasis ideal for leaders and managers as they strive to reframe how they think about and move past pre-conceived ideas or biases. In the book, the authors explain that bias is a natural part of the human condition and an inherent part of how our brains work. But unconscious bias often leaves us unaware of the results which can occur because of biased thinking. It can profoundly affect how we see and experience people, places and things. It influences how we make decisions, engage with others, and respond to various situations and circumstances. Ignoring our biases doesn’t eliminate their consequences, which can severely limit our own professional possibilities and those of our colleagues. We can negatively impact those with whom we work, which in turn affects results and organizational performance.

Unconscious bias can take many forms. It affects our thought processes, reasoning, what we remember, how we make decisions, how we relate to one another, and the talent we recruit, such as a preference for hiring someone because they look like us or have the same background, gender, age, or education. It can impact how we identify potential and who we choose to develop on a team, as we may unintentionally favor certain groups of people, regardless of capability. It might affect employee engagement and turnover, limit talent, and make it challenging for teams to work cross functionally. Unconscious bias can show up in the disappointment of a hiring manager when a candidate for a new position asks about maternity leave, or preferring the application of an Ivy League graduate over one from a state school, or assuming a man is more entitled to speak in a meeting than his female junior colleague.

“This book is our contribution to help advance a more inclusive world, where everyone can name and take responsibility for their own biases, can use empathy and curiosity to more effectively connect with others, and can choose courage to make positive changes at work. Discrimination, racial injustice, and injustice in any form have no place in the workplace or society. This includes race, color, sexual orientation, gender, identity, national origin, disability, age, veteran status, family or marital status, physical appearance, education religious beliefs, and geography. As human beings that are all connected, we can do better,” said Mark Murphy, FranklinCovey Senior Consultant.

The Leader’s Guide to Unconscious Bias is based on enduring principles and practices. It provides a proven framework for leaders at all levels to reframe the nature of bias, build the critical skills needed to transform behaviors, and to constructively address bias to enhance individual, team and organizational performance. The authors offer their unique perspective on the topic with heartfelt, inspiring stories about their experience with unconscious bias. They also provide more than thirty unique tools readers can use to help them overcome their own unconscious bias.

Readers will learn:

  • A framework for making progress on bias
  • How to identify bias in themselves and others with how they think and act in the workplace
  • The common traps that lead to biased thinking and when to pause and more fully consider decisions and behaviors
  • To cultivate deep and meaningful connections between people of varying backgrounds by using empathy and curiosity to expand mutual understanding and improve decision-making
  • To choose courage and engage with care and boldness in addressing the full spectrum of biases that limit people and constrain performance, such as race, gender, disability, sexual-orientation, education, socioeconomic status, and extroversion/introversion
  • To create a workplace culture in which everyone is respected, valued and can thrive and contribute their highest performance

See FranklinCovey On Leadership With Scott Miller Interview with Authors: https://resources.franklincovey.com/on-leadership-with-scott-miller/128-a-leaders-guide-to-uconscious-bias

As leaders and teams in organizations become more aware of and understand bias, they can address it by noticing and acknowledging their own biases to make progress on seeking, including, and valuing different perspectives. These behaviors build a culture in which individuals can contribute their best thinking and teams cultivate open and effective collaboration.

Pamela Fuller, FranklinCovey Thought Leader, Inclusion and Bias, said, “Leadership cannot be great if it isn’t inclusive, if it leaves anyone behind. In order to achieve results, leaders must ensure that each member of their team can confidently state, ‘I am a valued member of a winning team doing meaningful work in an environment of trust.’ Without inclusion and the sincere intent to explore biases that could be unintentionally excluding some, and therefore limiting performance, this statement cannot occur.”

The co-authors believe that every workplace can achieve its highest performance rate once biases are identified and appropriate action is taken so that employees are allowed to become whole people who are inspired to reach their highest potential. By recognizing unconscious bias and making true understanding and change a priority in the workplace, organizations can mitigate its negative consequences, unlocking the human potential of every person.

The new book bears the same name as FranklinCovey’s leadership solution, Unconscious Bias: Understanding Bias to Unleash Potential™. The work session establishes a connection between unconscious bias and individual, team and organizational performance. It provides organizations with a framework for addressing unconscious bias in order to build a culture that values diversity and inclusion. The solution is included in the FranklinCovey All Access Pass®, which provides passholders with unlimited access to FranklinCovey’s entire collection of best-in-class content. Passholders can assemble, integrate and deliver that content in an almost limitless combination through various delivery channels and integrated into existing training solutions. Passholders also have exclusive access to an implementation specialist and other add-on services, such as coaching, to ensure they are unleashing the full scope and power of All Access Pass to achieve their key business objectives.

To learn more about the solution, visit: Unconscious Bias: Understanding Bias to Unleash Potential. For more information about the FranklinCovey All Access Pass, visit: FranklinCovey’s All Access Pass.

ABOUT THE AUTHORS

Pamela Fuller

Pamela Fuller is FranklinCovey’s thought leader on unconscious bias, lead architect of its organizational solution, and one of the firm’s top global sales leaders. Pamela served as an architect of FranklinCovey’s Unconscious Bias work session and has delivered that session as well as DEI strategy discussions to thousands of leaders across the globe. She is also responsible for helping clients customize and implement learning and organizational-development solutions to meet their strategic objectives across FranklinCovey’s full catalog of learning solutions. After earning her MBA, Pamela served as a diversity analyst at the U.S. Department of Defense, focusing on human capital planning, diversity training, and statistical workforce analysis. She began her career in nonprofit fundraising and advocacy, always connected to inclusion and the voice of marginalized groups. Pamela currently lives in South Florida with her husband and children, where they spend their free time exploring all manner of superheroes.

Mark Murphy

Mark Murphy is a FranklinCovey Senior Consultant who has facilitated content successfully to clients worldwide for almost three decades. Through his own life experiences and extensive global travel, Mark is passionate about inclusion and bias and is an expert in helping clients create diversity in their cultures. He has helped organizations build effective and inclusive cultures in the public sector, the Fortune 500 companies, and the U.S. government. Mark is an expert in helping clients drive culture change. He works with clients to develop and execute strategies aligned to the client’s mission and vision that help drive large scale behavior change all the way to the frontline. Mark is phenomenal at developing leaders and individual contributors so organizations can meet their goals and reach new levels of effectiveness. Mark grew up in Colorado and has called Dallas home since 1994.

Anne Chow

Anne Chow is Chief Executive Officer of AT&T Business. She leads an organization of over 30,000 employees responsible for serving nearly 3 million business customers across the globe representing over $35B in revenues. With decades in the industry, Anne has led numerous global organizations through major transformations and developed countless role model relationships with clients, partners, and colleagues along the way. She’s known for being a professional and personal trailblazer and champion and catalyst for change in numerous circles. In addition to building world-class teams with winning cultures, some of Anne’s other passions include education, diversity and inclusion, advancing women in technology, and cultivating next-generation leaders. Most recently, Anne was named to Fortune’s 2020 Most Powerful Women’s List. With a Master of Business Administration with distinction from The Johnson School at Cornell University and a Bachelor of Science degree and Master of Engineering degree in Electrical Engineering from Cornell, Anne is also a graduate of the Pre-College Division of the Juilliard School of Music. She is also a proud board member of FranklinCovey.

ABOUT FRANKLIN COVEY CO.

Franklin Covey Co. (NYSE: FC) is a global, public company specializing in organizational performance improvement. We help organizations and individuals achieve results that require a change in human behavior. Our expertise is in seven areas: leadership, execution, productivity, trust, sales performance, customer loyalty and education. FranklinCovey clients have included 90 percent of the Fortune 100, more than 75 percent of the Fortune 500, thousands of small and mid-sized businesses, as well as numerous government entities and educational institutions. FranklinCovey has more than 100 direct and partner offices providing professional services in over 160 countries and territories.

Franklin Covey Co.

Debra Lund, 801-244-4474

[email protected]

KEYWORDS: United States North America Utah

INDUSTRY KEYWORDS: Other Consumer Publishing Entertainment Consulting Communications Professional Services Small Business Books Consumer

MEDIA:

Logo
Logo
Photo
Photo
FranklinCovey and Simon & Schuster Launch New Book, The Leader’s Guide to Unconscious Bias: How to Reframe Bias, Cultivate Connection, and Create High-Performing Teams (Photo: Business Wire)
Posted on

SINA to Hold Extraordinary General Meeting of Shareholders

PR Newswire

BEIJING, Nov. 20, 2020 /PRNewswire/ — SINA Corporation (the “Company” or “SINA”) (Nasdaq: SINA), a leading online media company serving China and the global Chinese communities, today announced that it has called an extraordinary general meeting of shareholders (the “EGM”), to be held at 10:00 a.m. Beijing Time on December 23, 2020, at Room Beijing, 1/F SINA Plaza No. 8 Courtyard 10 West, Xibeiwang East Road, Haidian District, Beijing 100193, People’s Republic of China, to consider and vote on, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger (the “Merger Agreement”) dated September 28, 2020 by and between New Wave Holdings Limited (“Parent”), New Wave Mergersub Limited, a wholly owned subsidiary of Parent (“Merger Sub”) and the Company, the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands in connection with the merger (the “Plan of Merger”) and the transactions contemplated thereby, including the merger.

Pursuant to the Merger Agreement and the Plan of Merger, at the effective time of the merger, Merger Sub will merge with and into the Company, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of Parent. If completed, the merger will result in the Company becoming a privately held company and its ordinary shares (“Ordinary Shares”) will no longer be listed on the NASDAQ Stock Market LLC. In addition, the Ordinary Shares will cease to be registered under Section 12 of the Securities Exchange Act of 1934.

The board of directors of the Company, acting upon the unanimous recommendation of the special committee of the board of directors of the Company comprised solely of independent directors unaffiliated with the buyer parties, approved the Merger Agreement, the Plan of Merger and the consummation of the transactions contemplated thereby, including the merger, and resolved to recommend that the Company’s shareholders vote FOR, among other things, the proposal to authorize and approve the Merger Agreement, the Plan of Merger, and the consummation of the transactions contemplated thereby, including the merger.

Shareholders of record as of the close of business in the Cayman Islands on November 20, 2020 will be entitled to attend and vote at the EGM.

Additional information regarding the EGM and the Merger Agreement can be found in the transaction statement on Schedule 13E-3 and the proxy statement attached as Exhibit (a)-(1) thereto, as amended, filed with the U.S. Securities and Exchange Commission (“SEC”), which can be obtained, along with other filings containing information about the Company, the proposed merger and related matters, without charge, from the SEC’s website (http://www.sec.gov). In addition, the Company’s proxy materials (including the definitive proxy statement) will be mailed to the Company’s shareholders.

SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS.

The Company and certain of its directors and executive officers may, under SEC rules, be deemed to be “participants” in the solicitation of proxies from the shareholders with respect to the proposed merger. Information regarding the persons who may be considered “participants” in the solicitation of proxies is set forth in the Schedule 13E-3 transaction statement relating to the proposed merger and the definitive proxy statement attached thereto. Further information regarding persons who may be deemed participants, including any direct or indirect interests they may have, is also set forth in the definitive proxy statement.

This announcement is for information purposes only and does not constitute an offer to purchase or the solicitation of an offer to sell any securities or a solicitation of any proxy, vote or approval with respect to the proposed transaction or otherwise, nor shall it be a substitute for any proxy statement or other materials that have been or will be filed with or furnished to the SEC.

About SINA

SINA is a leading online media company serving China and the global Chinese communities. Its digital media network of SINA.com (portal), SINA mobile (mobile portal and mobile apps) and Weibo (social media) enables internet users to access professional media and user generated content in multi-media formats from personal computers and mobile devices and share their interests with friends and acquaintances.

SINA.com offers distinct and targeted professional content on each of its region-specific websites and a full range of complementary offerings. SINA mobile provides news information, professional and entertainment content customized for mobile users through mobile applications and mobile portal site SINA.cn.

Weibo is a leading social media platform for people to create, distribute and discover content. Based on an open platform architecture, Weibo provides unprecedented and simple way for people and organizations to publicly express themselves in real time, interact with others on a massive global platform and stay connected with the world.

Through these properties and other product lines, SINA offers an array of online media and social media services to its users to create a rich canvas for businesses and advertisers to effectively connect and engage with their targeted audiences.

Safe Harbor Statements

This press release contains statements that express the Company’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 (the “Act”). These forward-looking statements can be identified by terminology such as “if,” “will,” “expected” and similar statements. Forward-looking statements involve inherent risks, uncertainties and assumptions. Risks, uncertainties and assumptions include: uncertainties as to how the Company’s shareholders will vote at the meeting of shareholders; the possibility that competing offers will be made; the possibility that financing may not be available; the possibility that various closing conditions for the transaction may not be satisfied or waived; and other risks and uncertainties discussed in documents filed with the SEC by the Company, as well as the Schedule 13E-3 transaction statement and the proxy statement filed by the Company. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. These forward-looking statements reflect the Company’s expectations as of the date of this press release. You should not rely upon these forward-looking statements as predictions of future events. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Contact

Investor Relations
SINA Corporation
Phone: +86 10 5898 3336
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/sina-to-hold-extraordinary-general-meeting-of-shareholders-301177983.html

SOURCE SINA Corporation

Posted on

Vail Resorts Announces Fiscal 2021 First Quarter Earnings Release Date

PR Newswire

BROOMFIELD, Colo., Nov. 20, 2020 /PRNewswire/ — Vail Resorts, Inc. (NYSE: MTN) announced today it will release the Company’s financial results for its fiscal first quarter 2021 ended October 31, 2020 after market close on Thursday, December 10, 2020. The Company will host a conference call at 5:00 p.m. eastern time that same day during which Company executives will review the financial results.

The call will be broadcast over the Internet at www.vailresorts.com. To listen to the call, go to the website and select the Investor Relations section. Those wishing to participate via telephone should dial (800) 367-2403 to be connected. Callers outside of the U.S. or Canada should dial (334) 777-6978.  

In addition, a replay of the call will be available two hours following the conclusion of the conference call through 8:00 p.m. eastern time on December 24, 2020. To access the replay, dial (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international), pass code 2470991. The call also will be archived at www.vailresorts.com.


About Vail Resorts, Inc. (NYSE: MTN)

Vail Resorts, Inc. (“Vail Resorts”), through its subsidiaries, is the leading global mountain resort operator. Vail Resorts’ subsidiaries operate 37 world-class destination mountain resorts and regional ski areas, including Vail, Beaver Creek, Breckenridge, Keystone and Crested Butte in Colorado; Park City in Utah; Heavenly, Northstar and Kirkwood in the Lake Tahoe area of California and Nevada; Whistler Blackcomb in British Columbia, Canada; Perisher, Falls Creek and Hotham in Australia; Stowe, Mount Snow, Okemo in Vermont; Hunter Mountain in New York; Mount Sunapee, Attitash, Wildcat and Crotched in New Hampshire; Stevens Pass in Washington; Liberty, Roundtop, Whitetail, Jack Frost and Big Boulder in Pennsylvania; Alpine Valley, Boston Mills, Brandywine and Mad River in Ohio; Hidden Valley and Snow Creek in Missouri; Wilmot in Wisconsin; Afton Alps in Minnesota; Mt. Brighton in Michigan; and Paoli Peaks in Indiana. Vail Resorts owns and/or manages a collection of casually elegant hotels under the RockResorts brand, as well as the Grand Teton Lodge Company in Jackson Hole, Wyoming. Vail Resorts Development Company is the real estate planning and development subsidiary of Vail Resorts, Inc. Vail Resorts is a publicly held company traded on the New York Stock Exchange (NYSE: MTN).

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vail-resorts-announces-fiscal-2021-first-quarter-earnings-release-date-301177827.html

SOURCE Vail Resorts, Inc.

Posted on

Donny Osmond Returns To The Las Vegas Stage With First-Ever Solo Residency At Harrah’s Las Vegas

Tickets go on sale starting Tuesday, Nov. 24, 2020

Shows begin Tuesday, Aug. 31, 2021

PR Newswire

LAS VEGAS, Nov. 20, 2020 /PRNewswire/ — Legendary entertainer and music icon, Donny Osmond, today announced his return to Las Vegas and the Caesars Entertainment family with his first-ever solo multi-year residency inside Harrah’s Showroom at Harrah’s Las Vegas, opening Tuesday, Aug. 31, 2021. 

“Donny Osmond has achieved a lifetime of remarkable milestones as an entertainer, including countless memories with us during his 11-year run at Flamingo,” said Caesars Entertainment Regional President Gary Selesner. “We’re thrilled to welcome him to the stage at Harrah’s Las Vegas next summer for an all-new show, and we look forward to sharing many more unforgettable moments with our guests and one of music’s most beloved stars.”

In an unprecedented and history-making deal for Harrah’s, Osmond’s return to stage will be an exciting, energy-filled musical journey of his unparalleled life as one of the most recognized entertainers in the world. Guests can expect a party as he performs his timeless hits, shares stories of his greatest showstopping memories and introduces brand new music in a completely reimagined song and dance celebration. The announcement comes almost exactly one year after the curtains closed for the final time on his previous record-breaking 11-year residency at Flamingo Las Vegas. Fans can once again experience an unforgettable night with Donny Osmond – exclusively at Harrah’s Las Vegas.   

Spanning five decades of entertainment, Donny Osmond has been a singer, actor, triple-threat television series host (talk show, game show, variety show) and best-selling author (his autobiography entered the UK bestseller chart at #1). Throughout his illustrious career, Donny has earned 33 gold records; selling over 100 million albums becoming a worldwide music legend. Currently Donny is hard at work on his 63rd album which is set to be all original music for the performer. Osmond’s debut at Harrah’s signifies the launch of his highly anticipated world tour.

“Las Vegas has been great to me and my family and in many ways, so this feels like a homecoming,” said Osmond. “I am incredibly excited to return to the entertainment capital of the world for my own solo residency at Harrah’s Las Vegas next summer, and I hope my fans are as excited as I am.”     

“The addition of the renowned talent of Donny Osmond to our already impressive entertainment lineup further cements Harrah’s position as a leading center-Strip property,” added Dan Walsh, Senior Vice President and General Manager of Harrah’s Las Vegas.  

Tickets will go on sale to the public starting Tuesday, Nov. 24 at 10 a.m. PT. Presale tickets for Caesars Rewards members as well as Ticketmaster customers will be available Monday, Nov. 23 from 10 a.m. to 10 p.m. PT. 

General ticket prices begin at $65, plus applicable tax and fees. Also, a limited number of VIP meet & greet packages are also available for performances Tuesdays through Fridays only. All tickets and packages can be purchased online at www.ticketmaster.com/donny. Performances will take place nightly from Tuesday to Saturday with all shows beginning at 8 p.m.

The available performances going on sale are:


August 2021: 31
September 2021: 1 – 4, 7 – 11, 14 – 18, 28 – 30  
October 2021: 1 – 2, 5 – 9, 12 – 16
November 2021: 2 – 6, 9 – 13, 16 – 20 

**For high-res photos and admat, click

here

**

About Harrah’s Las Vegas
With more than 2,500 hotel rooms and suites, Harrah’s Las Vegas is an affordable, welcoming resort where guests can break away from their daily routine in a playful atmosphere. The newly renovated Valley Tower features 1,600 stylish rooms with warm tones of gray and purple accents, as well as dark wood furnishings. Harrah’s Las Vegas features 87,000 square feet of casino space, a modern Race & Sports Book offering both live gaming and sports betting, and more than 25,000 square-feet of meeting and convention space. Six restaurants encompass everything from Toby Keith’s ‘I Love This Bar & Grill,’ which offers an all-American menu and live music nightly, to the chef-driven Fulton Street Food Hall, to the upscale setting of Ruth’s Chris Steak House, a romantic venue with breathtaking views of the Strip. Harrah’s outdoor bar, Carnaval Court, brings high energy to the Las Vegas Strip with live music and some of the world’s top flair bartenders who juggle and pour to perfection. A wide variety of entertainment options include Donny Osmond, magician Tape Face and adult revue X Country. Harrah’s Las Vegas is operated by a subsidiary of Caesars Entertainment, Inc. (NASDAQ: CZR). For more information, please visit harrahslasvegas.com or the Caesars Entertainment Las Vegas media room. Find Harrah’s Las Vegas on Facebook and follow on Twitter and Instagram.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/donny-osmond-returns-to-the-las-vegas-stage-with-first-ever-solo-residency-at-harrahs-las-vegas-301177948.html

SOURCE Caesars Entertainment, Inc.

Posted on

TD Asset Management Inc. Recognized in Three Categories at the 2020 Refinitiv Lipper Fund Awards for the 14th Year

Canada NewsWire

TORONTO, Nov. 20, 2020 /CNW/ – For the 14th year in a row, TD Asset Management Inc. (TDAM) was recognized in the Refinitiv Lipper Awards, with three TD Mutual Funds winning in their respective categories at the 2020 awards, announced yesterday.

The TD Mutual Funds, sub-advised by T. Rowe Price – TD Global Entertainment & Communications Fund, TD Science & Technology Fund and TD U.S. Mid-Cap Growth Fund (all Investor Series) – received awards in their respective categories as leading funds.

“Being recognized by Lipper is always a great honour for TDAM and its sub-advisors,” said Robert Vanderhooft, Chief Investment Officer, TDAM.  “These awards reflect the strong relationship we have enjoyed with T. Rowe Price over the years, and TDAM’s continuing commitment to deliver a broad range of innovative, compelling solutions that drive value for clients and advisors alike,” added Vanderhooft. “On behalf of our entire investment management team at TDAM, we are extremely appreciative for this acknowledgment.”

Each of the following TD Mutual Funds was recognized for providing attractive risk-adjusted returns relative to industry peers, across one or more performance periods:


WINNER


CLASSIFICATION


NUMBER OF FUNDS IN CATEGORY


AWARD PERIOD



TD Global Entertainment &
Communications Fund – Investor Series

Global Equity

139

10 Years



TD Science & Technology Fund –
Investor Series

Sector Equity

16

10 Years



TD U.S. Mid-Cap Growth –
Investor Series

U.S. Small/Mid
Cap Equity

17

10 Years

The Lipper Fund Awards, granted annually, highlight funds and fund companies that have excelled in delivering consistently strong risk-adjusted performance relative to their peers. The Lipper Fund Awards are based on the Lipper Leader for Consistent Return rating, which is a risk-adjusted performance measure calculated over 36, 60 and 120 months. The fund with the highest Lipper Leader for Consistent Return (Effective Return) value in each eligible classification per award universe wins the Lipper Fund Award. For more information, see lipperfundawards.com. Although Lipper makes reasonable efforts to ensure the accuracy and reliability of the data contained herein, the accuracy is not guaranteed by Lipper. 

Performance for TD Global Entertainment & Communications Fund – Investor Series for the period that ended Oct. 31, 2020 is as follows: 44.75% (1 year), 21.26% (3 years), 18.44% (5 years), 19.17% (10 years) and 13.33% (since inception on Nov. 28, 1997). The corresponding Lipper Leader ratings of the fund for the period that ended July 31, 2020 are as follows: N/A (1 year), 5 (3 years), 5 (5 years), 5 (10 years). 

Performance for TD Science & Technology Fund – Investor Series for the period that ended Oct. 31, 2020 is as follows: 55.28% (1 year), 19.13% (3 years), 21% (5 years), 23.22% (10 years) and 11.08% (since inception on Jan. 4, 1994). The corresponding Lipper Leader ratings of the fund for the period that ended July 31, 2020 are as follows: N/A (1 year), 4 (3 years), 4 (5 years), 5 (10 years).

Performance for TD U.S. Mid-Cap Growth Fund – Investor Series for the period ended Oct. 31, 2020 is as follows: 11.46% (1 year), 11.05% (3 years), 11.12% (5 years), 15.30% (10 years) and 10.54% (since inception on Jan. 4, 1994). The corresponding Lipper Leader ratings of the fund for the period that ended July 31, 2020 are as follows: N/A (1 year), 5 (3 years), 5 (5 years), 5 (10 years).

About the Refinitiv Lipper Fund Awards 

For more than 30 years and in over 17 countries worldwide, the highly-respected Refinitiv Lipper Awards have honoured funds and fund management firms that have excelled in providing consistently strong risk-adjusted performance relative to their peers and focus the investment world on top-funds. The merit of the winners is based on entirely objective, quantitative criteria. This, coupled with the unmatched depth of fund data, results in a unique level of prestige and ensures the award has lasting value. Renowned fund data and proprietary methodology is the foundation of this prestigious award qualification, recognizing excellence in fund management.

About Refinitiv
Refinitiv is one of the world’s largest providers of financial markets data and infrastructure, serving over 40,000 institutions in approximately 190 countries. It provides leading data and insights, trading platforms and open data and technology platforms that connect a thriving global financial markets community – driving performance in trading, investment, wealth management, regulatory compliance, market data management, enterprise risk and fighting financial crime.

About TD Asset Management Inc.

TD Asset Management (TDAM), a member of TD Bank Group, is a North American investment management firm. Operating through TD Asset Management Inc. in Canada and TDAM USA Inc. in the U.S., TDAM brings new thinking to investors’ most important challenges. TDAM offers investment solutions to corporations, pension funds, endowments, foundations and individual investors. Additionally, TDAM manages assets on behalf of almost 2 million retail investors and offers a broadly diversified suite of investment solutions including mutual funds, professionally managed portfolios and corporate class funds. Asset management businesses at TD manage $396 billion in assets as at September 30, 2020. Assets under management include TD Asset Management Inc., TDAM USA Inc., Epoch Investment Partners Inc. (Epoch) and TD Greystone Asset Management. All entities are wholly-owned subsidiaries of The Toronto-Dominion Bank. Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the fund facts and prospectus, which contains detailed investment information, before investing. The indicated rates of return are the historical annual compounded total returns for the period indicated including changes in unit value and reinvestment of distributions. The indicated rates of return do not take into account sales, redemption, distribution or optional charges or income taxes payable by any unitholder that would have reduced returns. Mutual funds are not guaranteed. Their values change frequently. Past performance may not be repeated.

All trademarks are the property of their respective owners.

SOURCE TD Asset Management Inc.

Posted on

Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

Research collaboration using ARCUS genome editing technology will initially include three gene targets, with right to select three additional gene targets; lead program focused on Duchenne Muscular Dystrophy

Precision will receive $100 million cash upfront and an equity investment by Lilly of $35 million; Precision also eligible to receive potential milestones up to $420 million per product, as well as tiered royalties on sales of licensed products

Precision to host conference call today at 8:30 a.m. ET

PR Newswire

INDIANAPOLIS, and DURHAM, N.C., Nov. 20, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Precision BioSciences, Inc. (Nasdaq: DTIL) today announced a research collaboration and exclusive license agreement to utilize Precision’s proprietary ARCUS® genome editing platform for the research and development of potential in vivo therapies for genetic disorders, with an initial focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets.

Genome editing technologies enable precise editing of the DNA of a living organism, opening up the possibility of correcting genetic problems at their source. ARCUS is a unique, proprietary, and versatile genome editing platform with attributes including specificity, ability to make a variety of efficient edits (knock-in, knock-out, and repair), and small size, thereby enabling a range of therapeutic editing. The platform is derived from a natural genome-editing enzyme called I-CreI, a homing endonuclease that can be optimized to control for potency and specificity.

Under the terms of the agreement, Precision will receive an upfront cash payment of $100 million, as well as an equity investment by Lilly of $35 million in Precision’s common stock. Precision is also eligible to receive up to $420 million in potential development and commercialization milestones per product, as well as tiered royalties ranging from the mid-single digits to low-teens on product sales should Lilly successfully commercialize a therapy from the collaboration. Precision will lead pre-clinical research and IND-enabling activities, with Lilly then assuming responsibility for clinical development and commercialization. Lilly will have the right to select up to three additional gene targets for this collaboration. Precision can co-fund clinical development of one product in exchange for an increased royalty rate on co-funded product sales.

“Gene-edited therapies are emerging as a promising approach to help patients afflicted with genetic conditions,” said Ruth Gimeno, Ph.D., vice president of diabetes and metabolic research at Lilly. “We look forward to working closely with Precision’s scientific team and leveraging their platform to develop and deliver breakthrough medicines for untreated genetic disorders.”

“This collaboration with Precision BioSciences represents another milestone in the realization of our vision to create medicines with transformational potential, using new therapeutic modalities such as gene editing to tackle targets and indications which were previously undruggable,” added Andrew Adams, Ph.D., vice president of new therapeutic modalities at Lilly.

“We look forward to working with Lilly to leverage our deep understanding of in vivo gene editing and experience with ARCUS to develop new therapies, including a potentially transformative treatment for Duchenne muscular dystrophy,” said Derek Jantz, chief scientific officer and co-founder of Precision BioSciences. “Collaborating with Lilly, a global healthcare leader with strong clinical and commercial experience in difficult-to-treat diseases, will help us accelerate our work aimed to solve genetic diseases with unique editing challenges.”

This transaction is subject to clearance under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act and other customary closing conditions. This transaction will be reflected in Lilly’s reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP). There will be no change to Lilly’s 2020 non-GAAP earnings per share guidance as a result of this transaction.

Precision BioSciences Conference Call and Webcast Information

Precision’s management team will host a conference call and webcast at 8:30 a.m. ET today, Friday, November 20, 2020 to discuss the collaboration. The dial-in conference call numbers for domestic and international callers are (866) 996-7202 and (270) 215-9609, respectively. The conference ID number for the call is 3135225. Participants may access the live webcast on Precision’s website https://investor.precisionbiosciences.com/events-and-presentations in the Investors and Media section under Events and Presentations. An archived replay of the webcast will be available on Precision’s website.

About ARCUS

ARCUS® is a proprietary genome editing technology discovered and developed by scientists at Precision BioSciences. It uses sequence-specific DNA-cutting enzymes, or nucleases, that are designed to either insert (knock-in), remove (knock-out), or repair DNA of living cells and organisms. ARCUS is based on a naturally occurring genome editing enzyme, I-CreI that evolved in the algae Chlamydomonas reinhardtii to make highly specific cuts in cellular DNA. Precision’s platform and products are protected by a comprehensive portfolio including more than 65 patents to date.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com. C-LLY

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

Lilly Forward-Looking Statement
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of a collaboration between Lilly and Precision BioSciences, and reflects Lilly’s current beliefs. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the collaboration, or that the collaboration will yield commercially successful products. For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, please see Lilly’s most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

Precision Forward-Looking Statements

Statements in this press release regarding Precision’s future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the expected benefits of the collaboration, that the collaboration will yield commercially successful products and the expected milestone and royalty payments. Forward-looking statements may be identified by words such as “anticipates,” “believe,” “continue,” “expect,” “intend,” “may,” “plan to,” “potential,” “will,” and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including without limitation, the risks referred to under the section “Risk Factors” in Precision’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, as such factors may be updated from time to time in Precision’s other filings with the SEC, which filings are accessible on the SEC’s website at www.sec.gov and the Investors & Media page of Precision’s website at https://investor.precisionbiosciences.com. All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, Precision has no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.


Refer to:                    

Mark Taylor; [email protected]; (317) 276-5795 (Lilly Media)

Kevin Hern; [email protected]; (317) 277-1838 (Lilly Investors)

Maurissa Messier; [email protected]; (Precision Media)

Alex Kelly; [email protected]; (Precision Investors)

 

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-precision-biosciences-announce-genome-editing-research-collaboration-and-license-agreement-301177966.html

SOURCE Eli Lilly and Company

Posted on

Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference

PR Newswire

CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and President, will participate in a virtual fire side chat at the 3rd Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 10:55 a.m. ET.

A live audio webcast may be accessed through the “Events” tab on the investor relations section of the Cogent website at: https://investors.cogentbio.com/events. A replay of the webcast will be available for 30 days following the event.

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent Biosciences is headquartered in Cambridge, MA. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, pertaining to the Company’s planned participation at an investor conference, which may include discussion of the Company’s business and operations, projected cash runways; future product development plans; and upcoming results from clinical trials. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in Cogent’s most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cogent-biosciences-to-participate-in-3rd-annual-evercore-isi-healthconx-virtual-conference-301177976.html

SOURCE Cogent Biosciences, Inc.

Posted on

Goodrich Petroleum To Participate At Upcoming Event

PR Newswire

HOUSTON, Nov. 20, 2020 /PRNewswire/ — Goodrich Petroleum Corporation (NYSE American: GDP) (the “Company”) today announced that the Company will participate in the Capital One Securities, Inc. Virtual Conference on December 7th through 9th, 2020.  Members of the Company’s management team will be participating in a series of virtual meetings with members of the investment community.

A copy of the latest corporate presentation will be available on the Company’s website at http://goodrichpetroleumcorp.investorroom.com/presentations.

Goodrich Petroleum is an independent oil and natural gas exploration and production company listed on the NYSE American under the symbol “GDP”.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/goodrich-petroleum-to-participate-at-upcoming-event-301177687.html

SOURCE Goodrich Petroleum Corporation

Posted on

HealthVerity and Medidata Announce Strategic Partnership to Advance Real World Evidence During and After Clinical Trials

With HealthVerity patient identity technology available across the Medidata platform, real world data is now readily accessible for patient safety monitoring, trial design and long-term therapeutic efficacy beyond the duration of clinical trials.

PR Newswire

PHILADELPHIA, Nov. 20, 2020 /PRNewswire/ — HealthVerity, the leader in privacy-protected data exchange, today announced a strategic collaboration with Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions to support the entire clinical development process, to significantly expand the understanding of clinical trial populations for enhanced insights during and post trial. With heightened necessity stemming from COVID-19, Medidata and HealthVerity have brought together their platforms, expertise and access to data to shape the effectiveness, design and impact of more real-time research. This collaboration will drive better patient outcomes in ongoing and prospective clinical trials, while delivering effectiveness and safety evidence reflective of populations beyond clinical trials.

We are witnessing the power of clinical trial and real-world data linkage in improving outcomes across disease areas.

This expanded partnership builds on the application of HealthVerity Census, the industry’s only real-time patient identity resolution technology, applied across the Medidata Rave Clinical CloudTM, the end-to-end clinical research platform, supporting more than 22,000 studies. With the unique and consistent patient identifier, the HealthVerity ID (HVID), available across the platform, researchers are now able to integrate patient-consented trial or registry data with traditional and novel real world data such as claims, EMR, labs, chargemaster, consumer, wearable sensors, digital interventions, and social determinants of health for studies at large.

“We are witnessing the power of clinical trials and real world data linkage in improving patient outcomes across disease areas. This advancement is occurring in multiple settings, and is potentially applicable in thousands of studies Medidata currently supports. We are seeing increasing interest especially across oncology and rare diseases where hybrid studies can meaningfully impact patient access to therapies,” said Arnaub Chatterjee, Senior Vice President of Product for Acorn AI, by Medidata, a Dassault Systèmes company. “We’re excited to expand upon our relationship with HealthVerity to enable life sciences companies to use RWD throughout the clinical development process.”

“The potential to combine HealthVerity’s leading ecosystem of 330 million patients from more than 75 healthcare and consumer sources with patient-level clinical trial data supported by Medidata, can benefit not only post-market clinical trial safety and effectiveness studies but can even be fed back into the design of the trial itself,” said Sandy Leonard, Vice President of RWE Platforms at HealthVerity. “Our commitment to decreasing the friction of technology and enabling the greater use of real-world data is exemplified with the pre-enabled linkage we now have with Medidata’s platform.”

About HealthVerity
For transformative, evidence-led healthcare companies, HealthVerity enables the creation and execution of unique end-to-end data strategies with privacy and HIPAA-compliance at the forefront.  With HealthVerity technologies directly embedded into the enterprise workflow and the largest, most flexible data ecosystem at their fingertips, our partners benefit from cloud solutions spanning expert patient identity resolution to secure data management and transformation. From activation to delivery, HealthVerity is the modern way to dataTM. To learn more about the HealthVerity platform, visit www.healthverity.com.

About Medidata
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,600+ customers and partners access the world’s most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata, The Operating System for Life SciencesTM.

Contact:
Abigail Stockwell
Senior Director of Marketing, HealthVerity
[email protected]  
856.562.7413

Paul Oestreicher

External Communications Director, Medidata
[email protected]
917.536.3523

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/healthverity-and-medidata-announce-strategic-partnership-to-advance-real-world-evidence-during-and-after-clinical-trials-301177757.html

SOURCE HealthVerity

Posted on

Acquisition of CPDQ’s 49% equity stake in 3 wind farms

PR Newswire

Boralex becomes the sole owner of 3 Quebec wind farms, with a 296 MW installed capacity

MONTREAL, Nov. 20, 2020 /PRNewswire/ – Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to announce that it has entered into a definitive agreement to acquire the full 49% equity stake held by the Caisse de dépôt et placement du Québec (“CDPQ”) in 3 wind farms in Quebec, already 51% owned by Boralex. CDPQ’s 49% equity stake represents 145 MW net installed capacity and the three wind farms represent a total capacity of 296 MW. Located in the Avignon RCM in Gaspésie and the Appalaches RCM in eastern Quebec, these farms are equipped with Enercon turbines and benefit from long-term power purchase agreements (“PPAs”) with Hydro-Québec Distribution, expiring between 2032 and 2033 with a weighted average remaining contract duration of nearly 12.5 years.

“We’re very pleased to announce our acquisition of CDPQ’s stake in high-quality wind farms that we already own 51% of and have managed for over two years following our acquisition of Invenergy’s stakes in these assets. Operating these wind farms provided the expected synergies and has yielded results 10% better than we had expected in 2019”, says Patrick Lemaire, Boralex’s President and CEO.

“This transaction strengthens our position in the wind industry in Canada and is perfectly aligned with the growth orientation of our strategic plan. Acquiring CDPQ’s stake will add significant cash flow for the coming years and a positive contribution to the company’s discretionary cash flow per share in the first year after the transaction closes. We also expect to generate additional operational and financial synergies in the coming years,” adds Patrick Decostre, Boralex’s Vice President and Chief Operating Officer.

As part of the acquisition, Boralex will pay a cash consideration of $121.5 million to CDPQ on closing, which may be supplemented by a conditional consideration of up to $4 million subject to the settlement of certain future conditions that need to be met. The closing is expected to take place at the end of November 2020, subject to standard closing conditions. Following this transaction, Boralex’s installed capacity will be 2,212 MW.

Highlights

  • Acquisition price: $121.5 million in cash payable at closing and an additional amount of up to $4 million after closing, subject to the settlement of certain conditions that need to be met;
  • Adds 145 MW net power to Boralex’s installed capacity;
  • Long-term contracts expiring between 2032 and 2033 with an average remaining duration of almost 12.5 years;
  • Additional annual contribution of the wind farms to Boralex’s results:
    • $31 million to combined EBITDA representing the acquisition of CDPQ’s 49% stake;
    • $62 million to EBITDA under IFRS representing 100% of EBITDA for wind farms that will now be consolidated in the Corporation’s financial statements;
    • $10 million or $0.10 per share to discretionary cash flows, an 8% increase over the consolidated amount generated by Boralex in 2019;
  • Additional operational and financial synergies expected.

Wind farm description

Des Moulins I wind farm (136 MW) is located in the Appalaches RCM in Quebec. This farm has 59 E-82 wind turbines. Des Moulins II wind farm (21 MW) is located in the Avignon RCM in Gaspésie, Quebec. This farm has nine E-92 wind turbines. Both farms are covered by an existing PPA that expires in December 2033.

Le Plateau I wind farm (139 MW) is located in the Avignon RCM in Gaspésie, Quebec. This park has 60 E-70 E4 wind turbines and is covered by an existing PPA that expires in March 2032.

Each wind farm is funded on a long-term basis through consortiums of international financial institutions. Financing consists of a combination of variable interest rate term loans (a large portion of which is covered by interest rate swaps) and notes or fixed rate loans. Project debt as at September 30, 2020, totalled $402 million (the 49% equity stake is therefore $197 million).

Questions relating to related party transactions
CDPQ holds approximately 17.28% of the Corporation’s issued and outstanding common shares as at November 20, 2020. The acquisition could be considered a “related party transaction” under MI 61-101 for the Protection of Minority Security Holders in Special Transactions (MI 61–101). The Corporation has availed itself of the exceptions for evaluation and approval of minority holders in paragraphs 5.5(a) and 5.7(a) in MI 61-101.

The two independent directors representing CDPQ on the Boralex board of directors did not participate in the discussions on the acquisition, and they abstained from voting on these matters.

About Boralex 
Boralex develops, builds and operates renewable energy power facilities in Canada, France, the United Kingdom and the United States. A leader in the Canadian market and France’s largest independent producer of onshore wind power, the Corporation is recognized for its solid experience in optimizing its asset base in four power generation types — wind, hydroelectric, thermal and solar. Boralex ensures sustainable growth by leveraging the expertise and diversification developed over 30 years. Boralex’s shares are listed on the Toronto Stock Exchange under the ticker symbol “BLX”. 

More information is available at www.boralex.com or www.sedar.com. Follow us on Facebook, LinkedIn and Twitter. 

Caution Regarding Forward-Looking Statements 

Some of the statements contained in this press release, including those regarding to the addition to the discretionary cash flow from the interests acquired, the accretion to discretionary cash flows per share of Boralex from the interests acquired, the expected EBITDA contribution from the interests  acquired, the expected additional operational and financial synergies, the expected closing date of the transaction, the conditional consideration payable following the closing, the Corporation’s business model and growth strategy are forward-looking statements based on current expectations, within the meaning of securities legislation. 

The forward-looking statements are based on material assumptions, including the following: assumptions about the performance the Corporation will obtain from the interests to be acquired, based on management’s estimates and expectations with respect to factors related to production and other factors; assumptions made about EBITDA margins; assumptions made about the situation in the sector and the economic situation in general, competition and the availability of financing. 

Although Boralex believes that the expectations reflected by the forward-looking statements presented in this news release are reasonable, Boralex would like to point out that, by their very nature, forward-looking statements involve risks and uncertainties such that its results or the measure it adopts could differ materially from those indicated by or underlying these statements, or could have an impact on the degree of realization of a particular forward looking statement. 

Unless otherwise specified by the Corporation, the forward-looking statements do not take into account the possible impact on its activities, transactions, non-recurring items or other exceptional items announced or occurring after the statements are made. There can be no assurance as to the materialization of the results, performance or achievements as expressed or implied by forward-looking statements. The reader is cautioned not to place undue reliance on such forward-looking statements. 

Unless required to do so under applicable securities legislation, Boralex management does not assume any obligation to update or revise forward-looking statements to reflect new information, future events or other changes. 

Cision View original content:http://www.prnewswire.com/news-releases/acquisition-of-cpdqs-49-equity-stake-in-3-wind-farms-301177954.html

SOURCE Boralex Inc.